The DOI matches its Crossref record.
High‐dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events
Abstract
High-dose intravenous immunoglobulin (IVIg) can increase blood viscosity in vitro and has been associated with cardiovascular or cerebrovascular thromboembolism. Because thromboembolic events were observed in two (3%) of 65 patients we treated with IVIg, we measured serum viscosity serially in 13 patients (five with amyotrophic lateral sclerosis [ALS], eight with IgM paraproteinemic polyneuropathy) before and immediately after each of three consecutive monthly infusions of IVIg. We correlated changes in viscosity with serial determinations of the total serum IgG, IgM, and IgA before and after each infusion. Serum viscosity increased after IVIg in all the patients by 0.1 to 1.0 centipoise (cp) (mean, 0.55 cp). In three ALS patients and in all the patients with paraproteinemic polyneuropathy, serum viscosity exceeded the upper limit of normal (normal, 1.5 to 1.9 cp) and increased as high as 2.6 cp. The increase in viscosity occurred immediately after completion of the infusion, declined over 1 month, and appeared to correlate best with the serum IgG level, which after the infusions was as high as 6,160 mg/dl (normal, 545 to 1,560 mg/dl). I conclude that IVIg increases serum viscosity and in many patients can cross the symptomatic threshold level. Because increased serum viscosity can impair blood flow and trigger a cardiovascular or cerebrovascular thromboembolic event, IVIg should be used judiciously and with concurrent monitoring of serum viscosity in elderly patients and patients with cryoglobulinemia, monoclonal gammopathies, high lipoproteins, or preexisting vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Dalakas, M. C. (2004) · JAMA · doi:10.1001/jama.291.19.2367 · Cited by 329
Self-citationReturn to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
Lünemann, J. D., Nimmerjahn, F., & Dalakas, M. C. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.253 · Cited by 301
Self-citationImmunopathogenesis and treatment of the guillain‐barré syndrome—part I
Hartung, H., Toyka, K. V., Pollard, J. D., & Harvey, G. K. (1995) · Muscle & Nerve · doi:10.1002/mus.880180202 · Cited by 288
Adverse Effects of Human Immunoglobulin Therapy
Stiehm, E. R. (2013) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2013.05.004 · Cited by 283
Metadata
- Authors
- Dalakas, M. C.
- Venue
- Neurology
- Published
- 1994-02
- Volume
- 44
- Issue
- 2
- Pages
- 223-223
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1990788350
- Cited by
- 274
- References
- 0
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High‐dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. https://app.cochat.ai/papers/10.1212/wnl.44.2.223
- The paper
- Dalakas, M. C. (1994). High‐dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology. https://doi.org/10.1212/wnl.44.2.223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.